Disease Markers / 2017 / Article / Tab 1 / Research Article
The Ratio of C-Reactive Protein/Albumin is a Novel Inflammatory Predictor of Overall Survival in Cisplatin-Based Treated Patients with Metastatic Nasopharyngeal Carcinoma Table 1 Baseline clinical features of 148 patients with metastatic nasopharyngeal carcinoma.
Characteristic Number (%) CRP/Alb < 0.189, number (%) CRP/Alb ≥ 0.189, number (%) valueGender (male/female) 124/24 (83.8/16.2) 63/15 (80.8/19.2) 61/9 (87.1/12.9) 0.373 Age, years (median/range) 45/24–72 45/26–70 43.5/24–72 0.765 KPS (median/range) 90/60–100 90/60–100 90/60–100 0.276 Number of involved sites (one/multiple) 69/79 (46.6/53.4) 42/36 (53.8/46.2) 27/43 (38.6/61.4) 0.071 Synchronous metastasis (yes/no) 43/105 (29.1/70.9) 20/58 (25.6/74.4) 23/47 (32.9/67.1) 0.368 Liver metastasis (yes/no) 56/92 (37.8/62.2) 28/50 (35.9/64.1) 28/42 (40/60) 0.615 Lung metastasis (yes/no) 69/79 (46.6/53.4) 38/40 (48.7/51.3) 31/39 (44.3/55.7) 0.623 Bone metastasis (yes/no) 61/87 (41.2/58.8) 28/50 (35.9/64.1) 33/37 (47.1/52.9) 0.184 Smoking (yes/no) 68/80 (45.9/54.1) 36/42 (42.1/53.8) 32/38 (45.7/54.3) 1.000 GPS (0/1/2) 88/46/14 (59.5/31.1/9.4) 52/20/6 (66.7/25.6/7.7) 36/26/8 (51.4/37.1/11.4) 0.169 Serum LDH, U/L (median/range) 202.5/25–2975 179.5/122–2821 230/25–2975 0.069 EBV-DNA, copies/mL (median/range) 4.82 × 104/0–9.13 × 107 3.49 × 104/0–9.87 × 106 5.32 × 105/0–9.13 × 107 0.013 Chemotherapy regimen (TP/PF/TPF) 12/45/91 (8.1/30.4/61.5) 7/26/45 (9/33.3/57.7) 5/19/46 (7.2/27.1/65.7) 0.605 Treatment response (CR + PR/PD + SD) 107/41 (72.3/27.7) 59/19 (75.6/24.4) 48/22 (68.6/31.4) 0.363 NLR (median/range) 3.3/1–35.2 2.8/1–14 4/1–35.2 0.001 PLR (median/range) 181/56.4–820 161/88–735 231/56.4–820 0.001 Hemoglobin, g/L (median/range) 131/43–171 132/43–171 123/82–162 0.019
CRP/Alb: C-reactive protein/albumin ratio; KPS: Karnofsky Performance Score; GPS: Glasgow Prognostic Score; NLR: neutrophil to lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; .